Triacontanol

Triacontanol: A Comprehensive Reference

1. Identity and Chemical Characterization

Chemical Names and Synonyms

1-Triacontanol, chemically known as triacontan-1-ol, is a naturally occurring saturated long-chain primary fatty alcohol with the molecular formula C₃₀H₆₂O and a molecular weight of 438.81 g/mol. This compound, characterized by its linear structure CH₃(CH₂)₂₈CH₂OH, is found in the epicuticular waxes of various plants, including rice and alfalfa, and in beeswax.

Among its many synonyms are 1-Hydroxytriacontane, melissyl alcohol, miraculan, myricyl alcohol, n-Triacontanol, nutron, prosopol, triacontyl alcohol, and ultria. Its CAS Registry Number is 593-50-0. According to Mandava (1979), TRIA is a secondary plant growth substance and cannot be considered as a phytohormone.

Physical and Chemical Properties

1-Triacontanol is a saturated straight-chain primary alcohol with 30 carbon atoms (C₃₀H₆₂O), exhibiting a melting point of 86.3–86.5°C. It is a saturated long-chain alcohol and, as a very high-molecular-weight fatty alcohol, it is highly hydrophobic and essentially insoluble in water under standard conditions. The compound is stable under normal temperatures and pressures.

Natural Sources

Triacontanol, sometimes abbreviated as "TRIA," is a naturally occurring fatty alcohol located in the epicuticular wax of plant leaves. This biodegradable and non-toxic substance is found in the highest concentrations in sugarcane and alfalfa. Beeswax is another noteworthy natural source.

Earlier studies have documented distribution of TRIA in the epicuticular waxes of widely diverse genera, such as California Croton (Croton californicus), blueberry (Vaccinium ashei), Brazilian palm (Copernica cerifera), runner bean (Phaseolus multiflorus), white clover (Trifolium repens), alfalfa (Medicago sativa), and physic nut (Jatropha curcas). Triacontanol is a natural compound isolated from many plant waxes and plant extracts, such as those from Mucuna aterrima, Heliotropium subulatum, Haloxylon salicornicum, and Phyllanthus amarus.

Triacontanol is a chemical substance present in instant tea waste and a relatively lesser amount in green tea and black tea. Within the dietary supplement category of policosanol — a mixture of long-chain alcohols extracted from sugarcane wax — octacosanol (62.9%), triacontanol (12.6%), and hexacosanol (6.2%) are the major components of the mixture.

Common Preparations and Forms

Because triacontanol is a solid crystalline wax at room temperature and is virtually insoluble in water, practical formulation presents a challenge. Stable colloidal dispersions of 1-triacontanol in water have been developed. Triacontanol, a C₃₀ linear primary alcohol, occurs in nature and can be extracted from alfalfa as a crystalline product. It is known in the art to be useful for stimulating growth in a wide variety of plants; however, field testing of various triacontanol formulations has generally produced inconsistent results. Stable colloidal dispersions are capable of more consistently stimulating plant growth by allowing uniform application of a large number of very small crystalline triacontanol particles. As a dietary supplement ingredient for humans, triacontanol is most commonly encountered as a component of policosanol tablet or capsule preparations, supplied as film-coated tablets of 5 and 10 mg. It is also available as a standalone botanical supplement in powder or tablet form, and as liquid colloidal suspensions for agricultural foliar application.

2. Historical and Traditional Context

Early Chemical Isolation

In 1933, Chibnall and others first isolated TA from alfalfa and regarded it as the main component of alfalfa leaf wax. Afterwards, TA was extracted from many plant waxes and insect waxes, and was eventually artificially synthesized, but its effect on plants was not yet known — it was regarded simply as a chemical constituent.

Discovery as a Plant Growth Regulator

In 1975, Ries discovered that TA has certain physiological activities. After a series of experiments, it was found that TA has an effect of increasing yields of corn, rice, wheat, tomato, carrot, cucumber, lettuce, and soybean. As early as 1975, Dr. S. K. Ries and associates at the Michigan Agricultural Experiment Station reported that coarsely chopped alfalfa hay, when applied to the soil as a band adjacent to row crops, could improve plant growth with respect to lettuce, rice, cucumbers, tomatoes, cauliflower, and field corn.

The plant growth regulatory activity of triacontanol was first formally discovered by Ries et al. (1977) in alfalfa (Medicago sativa L.). Alfalfa meal and chloroform extracts of the meal were shown to increase the growth and yield of several plant species. A crystalline substance isolated from the active fraction of alfalfa meal increased the dry weight and water uptake of rice seedlings when sprayed on the foliage or applied in nutrient culture. The substance was identified as triacontanol by mass spectrometry. Sprays containing this compound also increased the growth of corn and barley grown in soil. Authentic triacontanol produced a similar response over a wide range of concentrations on rice grown in nutrient cultures and tomatoes grown in soil.

Ries's discovery aroused great interest and attention of scholars in many countries. Laboratory-scale foliar application to field corn of a solution containing 0.01 mg per liter up to 1.00 mg per liter was reported. The compound subsequently became the subject of numerous agricultural patents and was adopted in large-scale commercial crop production, particularly across Asia.

Traditional Agricultural Use in Asia

Triacontanol (TRIA) is a natural plant growth regulator found in epicuticular waxes, and it has been used to enhance crop production on millions of hectares, particularly in Asia. Triacontanol at a small dosage of 50 mg/ha enhances the yield of crops such as tomato, cucumber, lettuce, maize, corn, and rice. Trials on tea plants showed an increase in harvestable yield by 25–30%, with a reduction in dormant shoots. The formulation sold under the commercial name "Miraculan" became widely used in India and other parts of South and Southeast Asia as a foliar spray on high-value horticultural and agronomic crops.

There is no established tradition of human consumption of isolated triacontanol in historical or ethnobotanical records. Its presence in human diets is incidental via consumption of foods derived from plants containing epicuticular waxes or beeswax. The compound has come to human health attention primarily because it is a significant component of policosanol, a supplement with a comparatively longer history of clinical investigation.

3. Key Constituents and Active Compound

Identity as a Single Compound

Unlike many botanical supplements that consist of complex mixtures, triacontanol is itself a single, well-defined chemical entity. Triacontanol has a molecular formula of C₃₀H₆₂O and a structural formula of CH₃—(CH₂)₂₈—CH₂—OH. When used as a dietary supplement, it may be delivered as pure or near-pure triacontanol, or as part of a policosanol mixture. In policosanol, octacosanol (C₂₈H₅₈O) comprises the majority (up to 66%) of the composition, alongside other components such as triacontanol (12%) and hexacosanol (7%).

Relationship to Policosanol

The major components of policosanol are typically octacosanol, triacontanol, and hexacosanol. Octacosanol is thought to be a key mediator of its potential lipid-modulating properties; however, to date, it is not clear how or why this mixture of alcohols would exert health benefits, and no optimal composition has been established.

4. Mechanisms of Action

Signal Transduction in Plants: The Adenosine Second-Messenger Hypothesis

Researchers have reported TRIA-mediated improvement in growth, yield, photosynthesis, protein synthesis, uptake of water and nutrients, nitrogen fixation, enzyme activities, and contents of free amino acids, reducing sugars, soluble protein, and active constituents of essential oil in various crops.

TRIA increased free amino acids, reducing sugars, and soluble protein of rice (Oryza sativa L.) and maize (Zea mays L.) within 5 minutes. TRIA elicited the appearance of L(+)-adenosine within 1 minute in the roots of plants, the shoots of which were sprayed with nanomolar concentrations of TRIA. Overwhelming assumptions led to the identification of a second messenger of TRIA as 9-β-L(+)-adenosine, i.e., 9H-purine-6-amine, 9-βl-ribofuranosyl (Ries et al. 1990). The discovery of TRIA-mediated formation/release of L(+)-adenosine (abbreviated as TRIM) may have elucidated the first step in the mechanism of TRIA action in plants.

The exogenous supply of triacontanol at minute concentrations can elicit several metabolic processes in a short span of time. Such growth regulators enhance the physiological efficiency of the cells and, thus, exploit the plant genetic potential to a large extent.

Effects on Photosynthesis and Enzyme Activity

Triacontanol enhances photosynthesis, increases plant enzyme activity, and promotes higher leaf area, which can significantly improve crop yield. Researchers have explored the beneficial effect of TRIA on various metabolic processes occurring during seed germination, seedling development, photosynthesis, and enzyme activities. TRIA also plays a pivotal role in inducing/establishing resistance against various abiotic stresses by regulating gene expression.

Antioxidant Enzyme Activation (Plants)

Triacontanol performs as a good scavenger of reactive oxygen species (ROS) by accelerating the activity of antioxidant enzymes (SOD, POD, CAT) and compatible solutes (proline, glycinebetaine, phenolic contents), which lead to improved gas exchange attributes and water relations and enhance the calcium and potassium contents while declining the sodium and chloride contents in plant cells.

TRIA application significantly increased shoot dry weight, chlorophyll content, antioxidant enzyme activities (superoxide dismutase, peroxidase, and catalase), and total polyphenol levels. The greatest antioxidant enzyme activity was observed for 5 µM TRIA, while the most significant secondary metabolite production was obtained for phytohormone-containing medium supplemented with 10 µM TRIA: total phenolic acid content (19.4 mg/g dry weight) was twice that of the control.

Interaction with Other Phytohormones

TRIA and its interaction with other phytohormones in regulating the physio-biochemical processes in counteracting stress-induced damages in plants has been studied. Exogenous triacontanol inhibits active oxygen accumulation by increasing antioxidant enzyme activity, down-regulating enzyme genes related to fruit softening and coloring, and regulating IAA, ETH, and ABA biosynthesis and signal transduction to delay senescence.

Potential Mammalian Mechanisms: CYP450 Induction

In animal models relevant to human pharmacology, triacontanol has been confirmed to have a potential anti-cancer effect, and studies have assessed whether co-administration of triacontanol alters drug exposure via inducing hepatic CYP3A1/2 activity. Triacontanol preferentially induced protein expression of CYP3A2 in a dose-dependent manner and of CYP3A1 at dosages of 120 and 180 mg/kg.

5. Scientific Evidence by Area of Use

5.1 Agricultural Crop Yield Enhancement

The most robust body of evidence for triacontanol concerns its use as a plant growth regulator. Various studies present strong evidence that application of TRIA, either to the root medium or to leaves, enhanced the growth and yield of vegetables and other crops, including agronomic and horticultural crops as well as medicinal and aromatic crop plants under normal and adverse conditions. However, further investigations are required to elucidate the possible role of TRIA on plant growth regulation, physiological activities, and secondary metabolite biosynthesis regarding medicinal and aromatic plants subjected to abiotic stress. This body of evidence is large, replicated across multiple crop species and geographies, and is considered well established within agricultural science, though it does not bear directly on human health.

5.2 Cardiovascular / Lipid Effects (via Policosanol)

Triacontanol is a constituent of policosanol, and some of the evidence base for cardiovascular effects of policosanol is therefore relevant contextually, though it cannot be attributed specifically to triacontanol alone.

Policosanol is a mixture of higher primary aliphatic alcohols isolated from sugar cane wax, whose main component is octacosanol. The mixture has been shown to lower cholesterol in animal models, healthy volunteers, and patients with type II hypercholesterolemia. A review of placebo-controlled lipid-lowering studies found that at doses of 10 to 20 mg per day, policosanol lowers total cholesterol by 17% to 21% and LDL cholesterol by 21% to 29% and raises HDL cholesterol by 8% to 15%.

However, the evidence base for policosanol overall is deeply contested. Most of the positive studies have been published by one research group in Havana, Cuba, where the original product was developed by Dalmer Labs Inc. In addition, there have been no studies published that examined clinical outcomes related to use of policosanol. Policosanol was originally tested in clinical trials for dyslipidemia in Cuba in the 1990s. The original studies had positive outcomes suggestive of cardiovascular benefit, but subsequent trials in other populations have shown no or only marginal benefits.

Octacosanol is thought to be a key mediator of its potential lipid-modulating properties, but to date it is not clear how or why this mixture of alcohols would exert health benefits. Although there are inconsistent data related to the efficacy of lowering cholesterol with policosanol therapy, a meta-analysis comprising 22 studies reported that policosanol could be used to lower lipid content and as a safe agent to elevate HDL-C levels.

Evidence strength: For lipid/cardiovascular effects, the evidence is mixed and cannot be attributed specifically to triacontanol. The body of research implicates octacosanol as the primary active component of policosanol. No clinical trial to date has tested isolated triacontanol in humans for cardiovascular outcomes.

5.3 Anticancer Activity

Triacontanol (TA), abundantly present in plant cuticle waxes and bee waxes, has been found to display promising anti-neoplastic potentials. A Chinese patent application (USPTO 7863337) proposed the use of triacontanol in preparation of human medicaments for treatment of cancers, specifically liver cancers.

Preclinical pharmacokinetic work on a PEGylated derivative demonstrated notable findings. PEGylated TA (named mPEG2K-SA-TA) substantially enhanced TA delivery with increased plasma exposure (19,791 vs. 336.25 ng·mL⁻¹·h⁻¹, p < .001), mean residence time (8.46 vs. 2.95 h), and elimination half-life (7.78 vs. 2.57 h) compared to those of original TA. Moreover, mPEG2K-SA-TA appeared to be safe in preliminary toxicological assessment. PEGylated TA also emerged as a functional carrier to deliver hydrophobic chemotherapeutic agents, since it readily self-assembled to micelles in aqueous solution. PEG-TA conjugate displayed superior anti-neoplastic activities and low toxicity, as well as facilitated the delivery of other hydrophobic agents.

Separately, PEGylated triacontanol (mPEG2k-b-TRIA) was developed as a dual-functional polymer with remarkable biocompatibility. The polymer could self-assemble to micelles. Docetaxel-loaded mPEG2k-b-TRIA micelles were fabricated; they achieved a desirable particle size of 93.7 nm, drug loading of 6.66%, and drug encapsulation efficiency of 89.87%. The drug release was based on first-order kinetics, enabling prolonged release.

Evidence strength: All anticancer evidence is currently preclinical — in vitro cell studies and animal models. No human clinical trials on triacontanol for cancer have been published. The compound is of pharmacological research interest but cannot be recommended for cancer prevention or treatment based on available evidence.

5.4 Abiotic Stress Tolerance (Plant Studies)

A substantial body of contemporary research has explored TRIA's capacity to protect crop plants against environmental stressors including salinity, heavy metals, drought, and temperature extremes. The role of triacontanol in strengthening salt and heavy metal stress-tolerance mechanisms has been extensively evidenced in many crops including wheat (Triticum aestivum), spinach (Spinacia oleracea), canola (Brassica napus), and rice (Oryza sativa).

In a controlled study on cucumber under salt stress, the study investigated the comparative performance of cucumber genotypes under salt stress (50 mmol L⁻¹) and stress alleviation through an optimized level of triacontanol at 0.8 mg L⁻¹. Triacontanol ameliorated the lethal impact of salt stress in all genotypes; it performs as a good scavenger of ROS by accelerating the activity of antioxidant enzymes (SOD, POD, CAT) and compatible solutes (proline, glycinebetaine, phenolic contents), which lead to improved gas exchange attributes and water relations.

TRIA plays essential roles in alleviating the stress-accrued alterations in crop plants via modulating the activation of the stress tolerance mechanisms. Being an endogenous plant growth regulator, TRIA facilitates numerous plant metabolic activities leading to better growth and development and plays essential roles in alleviating stress-accrued alterations in crop plants. This area of evidence is entirely restricted to plant science and has no established direct analogue in human physiology.

5.5 Secondary Metabolite Production

TRIA-mediated increases in dry matter production can influence the inter-relationship between primary and secondary metabolism, leading to increased biosynthesis of secondary products. This has practical implications for the production of medicinal and aromatic plant extracts, since higher concentrations of secondary metabolites (including phenolics, terpenoids, and essential oils) can result from TRIA treatment of cultivated plants.

6. Body Systems and Health Areas of Association

• Cardiovascular system: As a constituent of policosanol, triacontanol is associated indirectly with lipid-modulating and blood pressure effects explored in clinical trials on policosanol mixtures, though contribution of triacontanol specifically is unresolved.
• Oncology (preclinical): 1-Triacontanol recently shows promising anti-tumor activity in preclinical models. Research has focused on hepatocellular carcinoma and on using triacontanol as a biocompatible carrier molecule in nano-drug delivery systems.
• Drug metabolism / hepatic CYP enzymes: Triacontanol was confirmed to have a potential anti-cancer effect; studies assessed whether co-administration of triacontanol alters the exposure of docetaxel via inducing hepatic CYP3A1/2 activity. The concentration of docetaxel in rats pretreated with triacontanol for seven successive days was determined.
• Plant metabolic health (indirect dietary relevance): By enhancing concentrations of beneficial secondary metabolites in food crops, agricultural use of TRIA may indirectly affect the nutritional quality of plant-based foods.

7. Pharmacokinetics and Bioavailability

Formal pharmacokinetic data for triacontanol in mammals are very limited and derive from animal studies only. Elimination half-lives (t₁/₂) of 2.37 ± 1.23, 1.27 ± 0.49, and 2.07 ± 0.93 hours were measured after single oral administration of 30, 60, and 120 mg/kg of TA to rats. After oral administration, TA was extensively distributed in stomach and intestine.

The majority of TA was excreted via feces, with a cumulative excretion ratio during 72 hours of 26.68 ± 7.14%, but only 0.0023 ± 0.0015% and 0.0027 ± 0.0006% for urine and bile, respectively. The absolute bioavailability of TA was approximately 2.0%.

The very low oral bioavailability (~2%) is consistent with the highly lipophilic nature of the molecule. Concentration-time curves for 1-triacontanol and triacontanoic acid have been studied after administering a single oral dose of a policosanol mixture at 100 mg/kg. Triacontanol is metabolized to triacontanoic acid (a C₃₀ fatty acid). Pharmacokinetic data in humans are largely unpublished; studies with unlabeled octacosanol (a related compound) could not be evaluated because of the detection limit of analytic methods available. This limitation applies equally to triacontanol. No robust, dedicated human pharmacokinetic study of isolated triacontanol has been published in the peer-reviewed literature.

8. Dosage Forms and Reported Dosages

Dosage information for triacontanol varies considerably by application context.

• Agricultural foliar spray: As a plant growth regulator, 1-triacontanol functions primarily through foliar application at very low concentrations, typically in the range of 0.1 to 10 µM. Laboratory-scale foliar application to field corn used solutions containing 0.01 mg per liter up to 1.00 mg per liter.
• Agricultural root feed: Around 0.1 mg/L or 0.1 ppm is considered an efficacious dose for root feed.
• Agricultural field use: Triacontanol at a small dosage of 50 mg/ha enhances the yield of some crops.
• Policosanol supplement (human use): Policosanol, in which triacontanol is a 12.6% component, is supplied as film-coated tablets of 5 and 10 mg. At doses of 10 to 20 mg per day of the total policosanol mixture, studies have reported cholesterol-modulating effects.
• Preclinical anticancer studies (animal): Triacontanol was studied at dosages of 120 and 180 mg/kg in rats for CYP induction. Pharmacokinetic doses of 30, 60, and 120 mg/kg were administered to rats by single oral administration.

No established human therapeutic dose for isolated triacontanol has been validated in controlled clinical trials. Dosages used in preclinical animal models are not directly translatable to humans.

9. Safety Considerations and Drug Interactions

General Safety Profile

Triacontanol is embraced by researchers due to its low cost, ease of use, and lack of repercussions on the environment, and is acquired as a stress-relieving and growth-promoting molecule. As a natural component of many foods and beeswax, incidental dietary exposure to triacontanol at trace levels occurs regularly in humans without reported adverse effects. However, formal human safety studies for supplemental-dose triacontanol have not been published in peer-reviewed literature.

Oral Bioavailability Constraints

The absolute oral bioavailability of TA in rats was approximately 2.0%. This extremely low bioavailability — attributable to the compound's high lipophilicity and solid waxy form — means that most orally administered triacontanol is not absorbed. Efforts to improve delivery using PEGylated TA substantially enhanced plasma exposure (19,791 vs. 336.25 ng·mL⁻¹·h⁻¹, p < .001) and elimination half-life compared to original TA.

CYP3A Enzyme Induction: Clinically Significant Drug Interaction Risk

The most important documented safety consideration for triacontanol at supplemental or pharmacological doses is its capacity to induce hepatic cytochrome P450 enzymes, with potential for drug-drug interactions. The aim of one study was to assess whether co-administration of triacontanol alters the exposure of docetaxel via inducing hepatic CYP3A1/2 activity. The expression levels of CYP3A protein and mRNA were analyzed by western blot and real-time PCR.

The concentrations of docetaxel in rats pretreated with triacontanol were decreased, with 61.5%–61.9% decrease in AUC₀₋₂₄h and 65.7%–54.9% reduction in Cmax (at 120 and 180 mg/kg doses, respectively) compared with the control. Hepatic clearance of docetaxel was enhanced in vitro and in vivo, and CYP3A activity was up-regulated. This significant triacontanol-docetaxel interaction was largely due to the induction of CYP3A1/2, which brought useful information for clinical therapy when the combination is administered in humans.

This finding is experimentally derived from rat studies at very high doses (120–180 mg/kg), and direct extrapolation to humans at supplement doses requires caution. However, it suggests that high-dose triacontanol could potentially reduce the efficacy of CYP3A substrates — a class that includes many pharmaceuticals — by accelerating their hepatic clearance.

Formulation and Consistency Issues

Field testing of various triacontanol formulations has generally produced inconsistent and disappointing results in agricultural contexts, which is attributed to poor dispersibility of the waxy solid. This same physical-chemical challenge applies to oral supplement formulations in humans and raises questions about batch-to-batch consistency in commercially available products.

No Established Regulatory Monograph

As of the available evidence, no government health body (NIH ODS, NCCIH, EMA, EFSA) has published a formal monograph or safety assessment specifically for triacontanol as a dietary supplement ingredient. It is not listed in the WHO monograph series, the European Pharmacopoeia, or the German Commission E monographs as an evaluated herbal or supplement substance. Prior to recent pharmaceutical research interest, all reports focused on usage of triacontanol as a growth regulator and nutritional agent for vegetables, fruits, plants, and grain crops. No study about use of triacontanol in preparation of human medicaments had been reported before recent preclinical investigations.

10. Summary of Evidence Strength

• Agricultural plant growth promotion: Well-established, replicated across many species and geographies. High-quality evidence within agricultural science.
• Abiotic stress tolerance in plants: Well-documented in controlled studies. Relevant to crop science, not directly to human health.
• Lipid/cardiovascular effects in humans (via policosanol): Evidence exists but is contested; attributable primarily to octacosanol. No human clinical trials isolate triacontanol's specific contribution. Evidence is mixed to weak for the mixture as a whole in non-Cuban populations.
• Anticancer activity: Preliminary only — restricted to in vitro and animal models. No human clinical trials published. The preclinical findings are mechanistically interesting but not yet translatable to clinical practice.
• Drug interactions (CYP3A induction): Documented in animal models at high doses. Clinical relevance in humans at typical supplement doses is undetermined.
• Human pharmacokinetics and safety: Very limited data; no dedicated human clinical pharmacokinetic or safety studies published. Oral bioavailability is very low (~2% in rats).

References

• Ries SK et al. "Triacontanol: A New Naturally Occurring Plant Growth Regulator." Science, Vol. 195, No. 4284, 1977. DOI: 10.1126/science.195.4284.1339
• Naeem M, Khan MMA, Moinuddin. "Triacontanol: a potent plant growth regulator in agriculture." Journal of Plant Interactions, 7(2):129-142, 2012. DOI: 10.1080/17429145.2011.619281
• Sadak MS et al. "Triacontanol as a dynamic growth regulator for plants under diverse environmental conditions." Physiology and Molecular Biology of Plants, 2020. PMC7196594
• Verma T et al. "Triacontanol as a versatile plant growth regulator in overcoming negative effects of salt stress." Journal of Agriculture and Food Research, 10:100351, 2022.
• Wang C et al. "Effect of triacontanol on the pharmacokinetics of docetaxel in rats associated with induction of cytochrome P450 3A1/2." Xenobiotica, 2014. PMID: 24329500
• Wang C et al. "Investigation on pharmacokinetics, tissue distribution and excretion of 1-triacontanol in rats by gas chromatography-tandem mass spectrometry (GC-MS/MS)." Xenobiotica, 45(1):71-8, 2015. PMID: 25080280
• Chen Q et al. "Superior anti-neoplastic activities of triacontanol-PEG conjugate: synthesis, characterization and biological evaluations." Drug Delivery, 2018. PMC6060375
• Liu Y et al. "PEG-conjugated triacontanol micelles as docetaxel delivery systems for enhanced anti-cancer efficacy." Drug Delivery and Translational Research, 2019. PMID: 31444736
• Gouni-Berthold I, Berthold HK. "Policosanol: Clinical pharmacology and therapeutic significance of a new lipid-lowering agent." American Heart Journal, 143(2):356-65, 2002.
• Cubeddu LX et al. "Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial." American Journal of Clinical Nutrition, 2006.
• Kim JY et al. "Long-Term Consumption of Cuban Policosanol Lowers Central and Brachial Blood Pressure and Improves Lipid Profile With Enhancement of Lipoprotein Properties in Healthy Korean Participants." Frontiers in Physiology, 2018. PMC5939616
• Kim JY et al. "Cuban policosanol improves high-density lipoprotein cholesterol efflux capacity in healthy Japanese subjects." Frontiers in Nutrition, 2023.
• Sarwar M et al. "Triacontanol modulates salt stress tolerance in cucumber by altering the physiological and biochemical status of plant cells." Scientific Reports, 2021. PMC8718522
• Shi Y et al. "Triacontanol Promotes the Fruit Development and Retards Fruit Senescence in Strawberry: A Transcriptome Analysis." PMC7238246, 2020.
• Weremczuk-Jezyna I et al. "The Effect of the Stress-Signalling Mediator Triacontanol on Biochemical and Physiological Modifications in Dracocephalum forrestii Culture." PMC9735700, 2022.
• Wikipedia. "1-Triacontanol." (chemical identity, synonyms, natural sources)
• Alzheimer's Drug Discovery Foundation. "Policosanol: Cognitive Vitality Report." (policosanol composition and evidence review)
• Perveen S et al. "Triacontanol Improves Arsenic Stress Tolerance in Triticum aestivum L. Varieties." Journal of Soil Science and Plant Nutrition, 2024.
• ScienceDirect Topics. "Triacontanol — an overview." (aggregated research summaries)